VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
BHC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
BHCBausch Health Companies Inc.
$8.47$3.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. BHC
  4. Financial Ratios

Bausch Health Companies Inc. (BHC) Financial Ratios

Latest Ratios: P/E Ratio -3.8x · EV/EBITDA 5.4x · ROE 578.1%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

BHC Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$3.2B$2.6B$3.0B$2.9B$2.3B$9.9B$7.4B$10.5B$6.5B$7.3B$5.0B
Enterprise Value$23.0B$22.5B$23.6B$24.4B$22.5B$32.0B$30.7B$33.2B$30.0B$32.0B$34.3B
P/E Ratio →-3.8316.16———————2.42—
P/S Ratio0.280.250.310.330.281.170.921.220.770.840.52
P/B Ratio8.446.93——8.74—12.209.272.301.231.55
P/FCF1.732.602.353.85—8.679.218.615.103.742.81
P/OCF2.261.861.862.84—6.956.657.024.313.192.42

P/E links to full P/E history page with 30-year chart

BHC EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.192.452.782.773.793.833.863.593.673.55
EV / EBITDA5.416.638.3910.9412.1615.9712.2817.7369.0710.8214.93
EV / EBIT10.5511.4112.6515.0315.1518.7223.3824.7360.0957.7228.50
EV / FCF—22.4218.7432.06—27.9838.2827.1423.7316.3919.12

BHC Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin70.7%70.7%71.1%70.8%70.9%71.6%72.0%72.7%71.9%70.8%73.4%
Operating Margin21.3%21.3%16.1%11.0%5.6%5.3%8.4%-2.4%-28.4%1.2%-5.9%
Net Profit Margin1.5%1.5%-0.5%-6.8%-2.8%-11.2%-7.0%-20.7%-49.5%27.6%-24.9%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE578.1%578.1%—-665.2%-199.1%-332.0%-64.2%-90.3%-94.7%52.2%-51.9%
ROA0.6%0.6%-0.2%-2.2%-0.8%-3.1%-1.7%-5.8%-12.8%5.9%-5.2%
ROIC8.1%8.1%5.6%3.5%1.6%1.5%2.1%-0.6%-6.3%0.2%-1.2%
ROCE10.4%10.4%7.2%4.3%2.0%1.8%2.5%-0.8%-8.4%0.3%-1.4%

BHC Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity56.3656.36——79.87—39.5522.798.634.289.16
Debt / EBITDA6.256.257.7610.0511.2411.329.5713.8355.878.6012.98
Net Debt / Equity—52.84——77.70—38.5519.948.384.168.99
Net Debt / EBITDA5.865.867.349.6310.9311.029.3212.1054.228.3512.74
Debt / FCF—19.8316.3828.21—19.3129.0818.5218.6312.6516.32
Interest Coverage1.231.231.351.221.011.200.860.830.300.300.66

BHC Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.471.470.861.301.081.081.091.120.191.111.41
Quick Ratio1.081.080.620.940.800.890.860.94-0.060.871.11
Cash Ratio0.320.320.170.220.140.110.120.520.190.170.15
Asset Turnover—0.390.360.320.320.290.260.250.310.230.22
Inventory Turnover1.851.851.741.662.172.412.062.122.522.432.43
Days Sales Outstanding—83.4481.1583.2880.4276.8271.7178.0481.2389.1294.97

BHC Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield—6.2%———————41.3%—
FCF Yield57.7%38.5%42.5%26.0%—11.5%10.9%11.6%19.6%26.7%35.6%
Buyback Yield0.0%0.0%0.9%0.0%0.0%0.0%0.0%0.4%0.2%0.1%0.2%
Total Shareholder Yield0.0%0.0%0.9%0.0%0.0%0.0%0.0%0.4%0.2%0.1%0.2%
Shares Outstanding—$375M$368M$365M$362M$359M$355M$352M$350M$352M$347M

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Negative equity and heavy leverage

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Low Multiples Mask Leverage-Driven Equity Risk

Based on reported figures, BHC trades at 19.02x trailing earnings and 6.64x EV/EBITDA, multiples that look modest in isolation but sit against a stockholders' deficit that makes the P/B of 8.15x a distorted reference point.

The trailing P/E of 19.02 rests on earnings that swung from a $1.4B loss to a $436.0M profit within the last few quarters, so it reflects a volatile base rather than a stable earnings run-rate. The forward P/E of 1.71 implies the market expects a sharp earnings rebound, which warrants further investigation before treating it as a signal of value. EV/EBITDA of 6.64x against peer Prestige Consumer Healthcare at 8.86x suggests BHC is priced at a discount, which may reflect the market pricing in its debt load of roughly $20.7B.

Operating Gains Fail to Reach Net Earnings

As reported in financial statements, BHC's operating margin reached 33.4% in 2026Q3, yet net margin was only 14.8% and was negative in several earlier quarters, indicating that interest and other non-operating charges absorb much of the operating gain.

The gap between operating margin and net margin points to a capital structure where financing costs consume a large share of operating profit. Gross margin swung between 57.6% and 99.0% across the ten quarters, so the spread appears driven by reporting variability rather than stable pricing power. Given this, net margin is a more conservative measure of earning power than operating margin, though quarterly volatility limits confidence in any single period.

ROIC Recovering From a Thin Base

According to recent quarterly ratios, BHC's ROIC rose from 1.1% in 2025Q1 to 8.6% in 2026Q3, a notable improvement, though ROE remains undefined because of the stockholders' deficit.

The ROIC recovery appears to be driven primarily by margin expansion rather than improved capital efficiency, since asset turnover remains low at around 0.10 to 0.12. With ROE unusable due to negative book equity, ROIC is the more meaningful return measure here, but its latest reading still sits well below a typical cost of capital for a leveraged issuer. Investors should monitor whether the 2026Q3 level holds across subsequent periods.

Debt Service Strained Despite Coverage Swings

Based on BHC's reported figures, debt-to-EBITDA moved from roughly 25 to 36 times in earlier periods to 16.35 times in 2026Q3, while interest coverage swung from negative in 2026Q1 to 2.50 in the latest quarter.

Debt levels relative to EBITDA remain elevated by any conventional standard, and the improvement in 2026Q3 coincides with a sharp rebound in operating income rather than a visible reduction in debt. Interest coverage of 2.50 is adequate but leaves limited room for earnings shortfalls given the scale of obligations. Refinancing exposure and covenant terms are not disclosed in the supplied data, so the degree of near-term risk cannot be fully assessed from these figures.

Goodwill and Lumpy Cash Flow Overstate Strength

As reported in financial statements, goodwill of $9.8B exceeds the entire stockholders' deficit, and free cash flow margin ranged from 3.3% to 36.5%, so headline asset and cash metrics may overstate sustainable value and cash generation.

Goodwill accounts for roughly 38% of total assets, meaning the balance sheet's apparent scale depends heavily on acquisition accounting that may not reflect realizable value. The wide swing in free cash flow margin suggests working capital timing and one-off items are driving quarterly results more than a durable run-rate. Analysts should treat the 2026Q2 free cash flow margin of 36.5% as an outlier pending confirmation in later periods rather than as evidence of structural improvement.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open BHC Terminal

BHC Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

BHC — Frequently Asked Questions

Quick answers to the most common questions about buying BHC stock.

What is Bausch Health Companies Inc.'s P/E ratio?

Bausch Health Companies Inc.'s current P/E ratio is -3.8x. The historical average is 25.5x.

What is Bausch Health Companies Inc.'s EV/EBITDA?

Bausch Health Companies Inc.'s current EV/EBITDA is 5.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.6x.

What is Bausch Health Companies Inc.'s ROE?

Bausch Health Companies Inc.'s return on equity (ROE) is 578.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -17.6%.

Is BHC stock overvalued?

Based on historical data, Bausch Health Companies Inc. is trading at a P/E of -3.8x. Compare with industry peers and growth rates for a complete picture.

What are Bausch Health Companies Inc.'s profit margins?

Bausch Health Companies Inc. has 70.7% gross margin and 21.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Bausch Health Companies Inc. have?

Bausch Health Companies Inc.'s Debt/EBITDA ratio is 6.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.